149 BIO LLC

149 BIO LLC’s core capabilities cannot be determined due to insufficient award history. No contract performance data, NAICS codes, or agency engagements are available to infer specific technical services, operational focus, or specialized expertise. As a result, there is no verifiable basis to describe their technical domain, service offerings, or unique differentiators within the government contracting landscape. The absence of recent awards or historical contract records prevents any meaningful characterization of their capabilities in areas such as IT modernization, biotechnology support, laboratory services, or other bio-related federal missions often associated with the firm’s name. No agency relationships can be identified, as no contracting agencies are listed in the award history. Consequently, there is no evidence of sustained engagement with departments such as HHS, DOD, NIH, or CDC, nor any discernible pattern of work performed for federal, state, or local entities. The primary NAICS categories cannot be established due to a lack of contract data, making it impossible to define industry verticals or market positioning. While the firm’s name suggests potential alignment with biological sciences or life sciences support, no awarded contracts confirm this alignment or reveal whether services relate to research, diagnostics, bioinformatics, or regulatory compliance. 149 BIO LLC is structured as a 2L entity headquartered in Miami, Florida, with no government certifications on record. The company’s size, staffing, or operational scale cannot be inferred. Without certifications such as 8(a), HUBZone, or WOSB, and with no demonstrable contract performance, its government market presence remains unverified. The firm’s current footprint in the federal procurement ecosystem is not substantiated by available data.